Latest News and Events
Filter by
Selections
September 2, 2024
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Read MoreAugust 21, 2024
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Read MoreAugust 14, 2024
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
Read MoreAugust 8, 2024
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
Read MoreJuly 29, 2024
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreJune 25, 2024
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
Read MoreJune 24, 2024